Therapeutic treatments targeting abnormal morphogenesis of the vasculature, e.g. in cancer, have historically aimed to fully inhibit growth (anti-angiogenic therapy), primarily by targeting VEGF; however, many contraindications have now been identified [74]. Here, VEGFA is linked to cancer.